Skip to main content
ENSC logo

ENSC · Ensysce Biosciences, Inc.

Track ENSC — free
$0.42 +0.03 (+7.70%)
Market Cap
$7.45M
Shares
19.46M

ENSC metrics

58 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.39
Market cap
$7.45M

Price action

19 metrics
Price change (1W)
-3.7%
Price change (30D)
+38.6%
Price change (3M)
+48.1%
Price change (6M)
-23.9%
Price change (YTD)
-57.8%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
52-week high
$2.57
52-week low
$0.25
Change from 52-week high
-84.9%
Change from 52-week low
+54.6%
Annualized volatility
132.7%
Beta
1.3
RSI (14D)
53.4
Price vs SMA 50
+17.6%
Price vs SMA 200
-37.7%
Avg volume (3M)
14.42M
Relative volume
0.0
Average dollar volume
$6.39M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.46M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
1.7×
reciprocal yield 60.4%
P / book
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-169.4%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-08-18

Profitability

9 metrics
Gross margin
Operating margin
-281.3%
Trailing 12 months
Net margin
-280.5%
Gross profit (TTM)
Operating profit (TTM)
−$12.66M
Net income (TTM)
−$12.62M
Trailing 12 months
Diluted EPS (TTM)
$-2.52
FCF margin
Effective tax rate
11.9%

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$10.02

Growth

11 metrics
Revenue growth YoY
-15.1%
Year over year
Net income growth YoY
Revenue (TTM)
$4.50M
Trailing 12 months
EPS growth YoY
Shares change YoY
+491.9%
Year over year · more shares
Revenue CAGR (3Y)
+26.2%
Revenue CAGR (5Y)
+5.2%
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
Return on assets
-426.9%
Debt / equity
Current ratio
0.7
EBITDA (TTM)
Free cash flow (TTM)
Quick ratio
0.7
Interest coverage
-791.6
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
$676,704
Latest balance sheet
Cash & equivalents
$676,704
Total assets
$2.96M
Total debt

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.86M
Capital expenditures (TTM)
R&D (TTM)
$12.39M
SG&A (TTM)
$20.49M
Stock compensation (TTM)
R&D / revenue
275.2%
Stock compensation / revenue

Ownership (13F)

3 metrics
13F filers
18
13F filer change QoQ
+3
Institutional ownership
4.7%

Short interest

3 metrics
Short interest
5.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
$198,000
Insider-sentiment score
86 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1716947 CUSIP 293602504 13F (30d) 17 filings 17 filers Visit website Investor relations